RM

**RESERVE MEDS**

*RESERVED FOR YOU.*

PATIENT ACCESS BRIEF

# Roctavian in the UAE

*The MoHAP cross-border gene-therapy coordination pathway — indicative 2026*

HEMATOLOGY / GENE THERAPY · SEVERE HEMOPHILIA A

## The clinical situation

Roctavian (valoctocogene roxaparvovec) is a one-time intravenous AAV5 gene therapy delivering a functional B-domain-deleted factor VIII transgene to the liver, FDA-approved for adults with severe Hemophilia A (baseline factor VIII <1%). Developed by BioMarin. Eligibility is tightly gated: AAV5-capsid-antibody-negative titre, no history of factor VIII inhibitors, liver-health workup (ALT/AST bounds, no active HBV/HCV, no advanced fibrosis on elastography, no autoimmune hepatitis). Post-infusion patients are monitored for transaminitis, typically with a tapering corticosteroid course to protect transgene expression. Factor VIII activity, LFTs, and AAV safety parameters are tracked for at least five years.

## The pathway, 6 steps

1. **Consultation with your haematologist.** Bleed history, prior prophylaxis or on-demand regimen, inhibitor history, and liver status.
2. **Eligibility workup.** AAV5 capsid antibody titre, factor VIII inhibitor assay, hepatic panel with elastography, hepatitis serology, autoimmune hepatitis screen.
3. **Treatment-centre identification.** Reserve Meds coordinates referral to a qualified gene-therapy centre operating under BioMarin's QTC model.
4. **MoHAP medical-referral dossier.** Filed by your physician with supporting clinical rationale and return-to-home surveillance plan.
5. **Cross-border travel & single infusion.** One IV infusion at the qualified centre; early post-infusion monitoring and corticosteroid management.
6. **Handover to UAE haematology team.** Structured multi-year surveillance plan for factor VIII activity, LFTs, and AAV safety parameters.

### Indicative economics

**Reference US list price:** ~USD 2.9M one-time product; total cost of care (workup, infusion, monitoring, caregiver travel) runs materially higher. Reserve Meds issues a transparent all-in quote at intake.

### Indicative first-infusion timing

**10–20 weeks** from intake to infusion, driven by eligibility workup, treatment-centre calendar, and travel coordination. Indicative — not guaranteed.

## Reserve Meds's role

**Coordination.** Referral to qualified gene-therapy treatment centre aligned with BioMarin's QTC model. **Documentation.** Coordination kit for your haematologist and MoHAP medical-referral review, keyed to the Roctavian gene-therapy rationale.

**Logistics.** Cross-border travel coordination including caregiver support and accommodation guidance. **Concierge case lead.** Named point of contact for family and care team across the multi-year surveillance horizon. **We are a coordinator** — not the prescriber, not the treatment centre. All clinical decisions remain with your treating haematologist and the QTC team.

*COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST*

**Join the Roctavian × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

reservemeds.com/access-guides/roctavian-uae.html

SCAN TO JOIN



**reservemeds.com** · hello@reservemeds.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team